47 results on '"Comella, Cynthia"'
Search Results
2. Injections of incobotulinumtoxina at intervals less than 10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard injection intervals
3. The effect of botulinum toxin on anxiety in cervical dystonia: A prospective, observational study
4. Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis
5. Treatment of Cervical Dystonia Using Shorter IncobotulinumtoxinA Injection Intervals Improves Patient-Reported Outcomes in Those With Inadequate Benefits From Standard Intervals
6. Injections of IncobotulinumtoxinA at Intervals Less Than 10 weeks Are Effective and Safe for Cervical Dystonia Patients With Inadequate Benefit From Standard Injection Intervals
7. Development of an App-Based Patient-Centered Outcome (PCO) Measure for Dystonia
8. A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia
9. Head tremor in cervical dystonia: Quantifying severity with computer vision
10. Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy
11. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study
12. Diagnostic criteria for blepharospasm: A multicenter international study
13. Patient experiences of symptom re-emergence: Findings from 2 online patient surveys in spasticity and cervical dystonia
14. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia
15. Management of symptom re-emergence in patients living with spasticity and cervical dystonia: Findings from 2 online patient surveys
16. It's tricky: Rating alleviating maneuvers in cervical dystonia
17. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study
18. Recent developments in drug-induced movement disorders: a mixed picture
19. Progressive Encephalomyelitis With Rigidity and Myoclonus Syndrome Presenting as Catatonia
20. Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study
21. Editorial: TOXINS 2019
22. Outcomes of week-24 completers and subjects who had follow-up beyond week 24 after a single treatment of daxibotulinumtoxinA for injection (RT002): Results of a phase 2, open-label (Level II), dose-escalating study in isolated cervical dystonia
23. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale
24. Systematic review of botulinum toxin treatment for oromandibular dystonia
25. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?
26. Dystonia: Then and now
27. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
28. Comparison of methodology, patient characteristics, and treatment results from ANCHOR-CD (abobotulinumtoxinA neurotoxin: Clinical and health economics outcomes registry in cervical Dystonia) and other registry studies of botulinum toxin type A in cervical Dystonia
29. A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia
30. SystemATic Review of Botulinum toxin treatment for Oromandibular dystonia
31. Secured web-based video repository for multicenter studies
32. Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)
33. 50. Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxin A efficacy (CD PROBE)
34. Subthalamic nucleus—sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease
35. 51. The many causes of secondary nonresponse to botulinum toxin treatment
36. 26. Differences in the management of cervical dystonia in the United States (US) versus Europe (EU): the patients’ perspective
37. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
38. Beyond a motor disorder: A prospective evaluation of sleep quality in cervical dystonia
39. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
40. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
41. Treatment of focal dystonias with botulinum neurotoxin
42. Variability of EMG patterns: A potential neurophysiological marker of Parkinson’s disease?
43. Sleep Disorders in Parkinson's Disease
44. Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial
45. Association of daytime napping and Parkinsonian signs in Alzheimer's disease
46. Botulinum toxins for the treatment of cervical dystonia
47. Restless Legs Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.